Biogen Announces Late Breakers and Additional New Data
Presentations at the 2021 Clinical Trials on Alzheimer’s Disease
(CTAD) Meeting
Biogen Inc. (Nasdaq: BIIB) announced the company will present
a variety of new data from its Alzheimer’s disease product
portfolio and clinical development pipeline at the upcoming annual
Clinical Trials on Alzheimer’s Disease conference (CTAD), held
November 9-12 virtually and in Boston, Massachusetts. Biogen’s
contributions to the conference are driven in part by analyses from
the largest clinical trial dataset in early Alzheimer’s disease
research. This includes over 3,000 patients in Phase 3 trials and
approximately 1,700 patients in the ADUHELM (aducanumab-avwa)
redosing trial, EMBARK.
A late breaking presentation will highlight important new data
from over 7,000 plasma samples from the ADUHELM Phase 3 trials
that, for the first time, examines the effect of ADUHELM on plasma
phosphorylated tau181 (p-Tau181) and its correlation to amyloid
beta plaques and disease progression, as measured by clinical
decline endpoints, in patients with early Alzheimer’s disease. The
accumulation of amyloid beta plaques and tangles of tau proteins in
brain cells are the two defining pathologies of Alzheimer’s
disease.
“We collected an unprecedented sample size—approximately 7,000
plasma samples from more than 1,800 patients—to provide robust
answers to questions about the correlation between plasma pTau
reduction, amyloid beta plaque levels and clinical decline in
Alzheimer’s disease. We are eager to engage the scientific
community with the findings from this comprehensive dataset,” said
Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. “The
clinical insights we can derive from our data at CTAD are
meaningful. These can help inform clinician, patient and caregiver
choice and future treatment decisions, as well as advance the
field’s understanding of this devastating disease.”
The data will be discussed at the virtual oral presentation and
roundtable: “Dose and time dependent changes in plasma ptau181 in
patients treated with aducanumab in the ENGAGE and EMERGE trials,”
on Thursday, November 11, at 5:10 p.m. EST.
Biogen will also present data from over 1,800 patients that were
screened for the EMBARK re-dosing trial with ADUHELM, to shed light
on the impact of stopping treatment in clinical trials. Patients
who were enrolled in the ADUHELM trials when they were discontinued
in 2019 later re-enrolled in the EMBARK trial, after a lengthy
off-treatment period of an average of 1.7 years. Some of these
patients had been on treatment for more than 4 years in the PRIME
Phase 1b long-term extension, as well as for up to 18 months in the
Phase 3 trials, EMERGE and ENGAGE. Disease progression and amyloid
beta plaque levels during this extended discontinuation of
Alzheimer’s disease treatment will be examined in the Virtual Oral
Presentation, “Baseline EMBARK data from EMERGE, ENGAGE, and PRIME
participants in the EMBARK re-dosing study,” on Tuesday, November
9, at 8:00 a.m. EST.
In addition, a poster titled, “Urgency to treat before it’s too
late: Daily transitions to moderate AD dementia in the US and
Europe,” will examine how many people are estimated to progress
daily from mild cognitive impairment due to Alzheimer's disease to
mild Alzheimer’s disease, and from mild Alzheimer’s disease to
moderate Alzheimer's disease, pointing to the urgency for earlier
detection, diagnosis and treatment.
Abstract details:
- ADUHELM
- Late Breaking Virtual Oral
Presentation: Baseline EMBARK data from EMERGE, ENGAGE, and PRIME
participants in the EMBARK re-dosing study (Cohen S; #LBR2) –
Available virtually starting on Tuesday, November 9, 8:00 a.m.
EST
- Late Breaking Virtual Oral
Presentation: Defining a standardized MRI acquisition protocol to
be proposed to ICARE AD-US sites for baseline and ARIA monitoring
(Benzinger T; #LBR4) – Available virtually starting on Tuesday,
November 9, 8:00 a.m. EST
- Late Breaking Virtual Oral
Presentation: Dose and time dependent changes in plasma ptau181 in
patients treated with aducanumab in the ENGAGE and EMERGE trials
(Hanson O, #Late Breaking Readout Roundtable 8) – Thursday,
November 11, 5:10 p.m. EST
- BIIB092
- Late-Breaking Virtual Oral Presentation: Top-line results from
TANGO, a Phase 2 study of gosuranemab in participants with mild
cognitive impairment due to Alzheimer’s disease and mild
Alzheimer’s disease (Shulman; #LBR5, Shulman) – Available virtually
starting on Tuesday, November 9, 8:00 a.m. EST
- BIIB076
- Virtual Oral Presentation: Results of A Phase 1, Randomized,
Blinded, Placebo-Controlled, Single-Ascending-Dose Study to
Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076
in Healthy Volunteers and Subjects With Alzheimer’s Disease (Ratti
E; #ROC16) – Available virtually starting on Tuesday, November 9,
8:00 a.m. EST
- General Alzheimer’s Disease
- Poster Presentation: Urgency to treat
before it’s too late: Daily transitions to moderate AD dementia in
the US and Europe (Maserejian N; #LP23) – Wednesday, November 10,
through Friday, November 12.
- Poster Presentation: Distribution and
baseline characteristics of participants with rapid progressing
Alzheimer’s Disease as measured by CDR-SB over 78 weeks in the
National Alzheimer’s Coordinating Center (NACC) (Gillis C; #P63) -
Wednesday, November 10, through Friday, November 12.
- Poster Presentation: Updated U.S.
prevalence estimates accounting for racial and ethnic diversity for
trials and therapies targeting mild cognitive impairment due to
Alzheimer’s disease (AD) and mild AD dementia (Maserejian N; #LP22)
- Wednesday, November 10, through Friday, November 12.
- Poster Presentation: Sigmoid
methodology allows early prediction of cognitive decline towards
Alzheimer’s disease across several cognitive domains (Doecke J;
#RP25) - Wednesday, November 10, through Friday, November 12.
- Poster Presentation: Global prevalence
of Alzheimer’s disease across disease stages (Gustavsson A; #RP36)
- Wednesday, November 10, through Friday, November 12.
- Frontotemporal Dementia
- Poster Presentation: Estimates of Frontotemporal Dementia by
geographic regions (Gillis C; #P61) - Wednesday, November 10,
through Friday, November 12.
Biogen will host webcasts of its oral presentations on EMBARK
and plasma ptau181 on the investors section of Biogen’s website at
investors.biogen.com concurrent with the presentation times
indicated above. Following the webcasts, archived versions will be
available on the website.
About
ADUHELM® (aducanumab-avwa)
injection 100 mg/mL solutionADUHELM is indicated for the
treatment of Alzheimer’s disease. Treatment with ADUHELM should be
initiated in patients with mild cognitive impairment or mild
dementia stage of disease, the population in which treatment was
initiated in clinical trials. There are no safety or effectiveness
data on initiating treatment at earlier or later stages of the
disease than were studied. This indication is approved under
accelerated approval based on reduction in amyloid beta plaques
observed in patients treated with ADUHELM. Continued approval for
this indication may be contingent upon verification of clinical
benefit in confirmatory trial(s).
Aducanumab-avwa is a monoclonal antibody directed against
amyloid beta. The accumulation of amyloid beta plaques in the brain
is a defining pathophysiological feature of Alzheimer’s disease.
The accelerated approval of ADUHELM has been granted based on data
from clinical trials showing the effect of ADUHELM on reducing
amyloid beta plaques, a surrogate biomarker that is reasonably
likely to predict clinical benefit, in this case a reduction in
clinical decline.
ADUHELM can cause serious side effects including: Amyloid
Related Imaging Abnormalities or “ARIA”. ARIA is a common side
effect that does not usually cause any symptoms but can be serious.
Although most people do not have symptoms, some people may have
symptoms such as: headache, confusion, dizziness, vision changes
and nausea. The patient’s healthcare provider will do magnetic
resonance imaging (MRI) scans before and during treatment with
ADUHELM to check for ARIA. ADUHELM can also cause serious allergic
reactions. The most common side effects of ADUHELM include:
swelling in areas of the brain, with or without small spots of
bleeding in the brain or on the surface of the brain (ARIA);
headache; and fall. Patients should call their healthcare provider
for medical advice about side effects.
As of October 2017, Biogen and Eisai Co., Ltd. are collaborating
on the global co-development and co-promotion of aducanumab.
Please click here for full Prescribing Information,
including Medication Guide, for ADUHELM.
About BiogenAs pioneers in neuroscience, Biogen
discovers, develops, and delivers worldwide innovative therapies
for people living with serious neurological diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize
winners Walter Gilbert and Phillip Sharp. Today, Biogen has the
leading portfolio of medicines to treat multiple sclerosis, has
introduced the first approved treatment for spinal muscular
atrophy, and is providing the first and only approved treatment to
address a defining pathology of Alzheimer’s disease. Biogen is also
commercializing biosimilars and focusing on advancing the
industry’s most diversified pipeline in neuroscience that will
transform the standard of care for patients in several areas of
high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative
to address the deeply interrelated issues of climate, health, and
equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil
fuels across the company’s operations, build collaborations with
renowned institutions to advance the science to improve human
health outcomes, and support underserved communities.
The company routinely posts information that may be important to
investors on its website at www.biogen.com. To learn more,
please visit www.biogen.com and follow Biogen on social
media
– Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, about the
potential clinical effects of ADUHELM; the potential benefits,
safety and efficacy of ADUHELM; the treatment of Alzheimer’s
disease; results from the EMBARK study; the anticipated benefits
and potential of Biogen’s collaboration arrangements with Eisai;
clinical development programs, clinical trials and data readouts
and presentations; and risks and uncertainties associated with drug
development and commercialization. These statements may be
identified by words such as “aim,” “anticipate,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,”
“possible,” “potential,” “will,” “would” and other words and terms
of similar meaning. Drug development and commercialization involve
a high degree of risk, and only a small number of research and
development programs result in commercialization of a product.
Results in early stage clinical trials may not be indicative of
full results or results from later stage or larger scale clinical
trials and do not ensure regulatory approval. You should not place
undue reliance on these statements or the scientific data
presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation unexpected concerns
that may arise from additional data, analysis or results obtained
during clinical trials; the occurrence of adverse safety events;
risks of unexpected costs or delays; the risk of other unexpected
hurdles; failure to protect and enforce Biogen’s data, intellectual
property and other proprietary rights and uncertainties relating to
intellectual property claims and challenges; risks associated with
current and potential future healthcare reforms; product liability
claims; third party collaboration risks; and the direct and
indirect impacts of the ongoing COVID-19 pandemic on Biogen’s
business, results of operations and financial condition. The
foregoing sets forth many, but not all, of the factors that could
cause actual results to differ from Biogen’s expectations in any
forward-looking statement. Investors should consider this
cautionary statement as well as the risk factors identified in
Biogen’s most recent annual or quarterly report and in other
reports Biogen has filed with the U.S. Securities and Exchange
Commission. These statements are based on Biogen’s current beliefs
and expectations and speak only as of the date of this news
release. Biogen does not undertake any obligation to publicly
update any forward-looking statements, whether as a result of new
information, future developments or otherwise.
BIOGEN MEDIA
CONTACT: |
BIOGEN
INVESTOR CONTACT: |
Ashleigh Koss |
Mike Hencke |
+ 1 908 205 2572 |
+1 (781) 464-2442 |
Public.affairs@biogen.com |
IR@biogen.com |
Biogen (TG:IDP)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biogen (TG:IDP)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024